Shire Pharmaceuticals Group PLC
http://www.shire.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shire Pharmaceuticals Group PLC
Risks For Pharma Industry Remain As BIO Shifts Course On BIOSECURE Act
Trade group’s break from WuXi Apptec allows BIO to reset its lobbying approach under its new CEO but doesn’t negate the business and supply chain disruptions that biopharma would feel from the proposed legislation.
WuXi AppTec Quits BIO As Group Endorses BIOSECURE Act
BIO chairman Ted Love had said at BIO CEO last month that “damaging” the company could have unintended consequences.
US Senate Advances BIOSECURE Legislation As China Biotech Security Heats Up
The US Senate moves closer to new legislation that would restrict Chinese "biotech companies of concern” from operating in the US, potentially causing broad and far-reaching impact.
First Digital Therapeutic App Filed For Approval In Expanding Japan ADHD Market
A pioneering approval filing for a therapeutic app by Shionogi is set to herald expansion of ADHD therapies beyond the pill in Japan, along with growth in the pediatric segment for the disorder.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Advanced BioHealing, Inc. (renamed Shire Regenerative Medicine)
- AesRX LLC
- Baxalta Incorporated
- BIKAM Pharmaceuticals Inc.
- Chatham Therapeutics
- Dyax Corp.
- FerroKin BioSciences, Inc.
- Fibrotech Therapeutics
- Foresight Biotherapeutics Inc.
- Gambro AB
- Immuno-US
- Jerini AG
- Lotus Tissue Repair
- Lumena Pharmaceuticals
- Meritage Pharma, Inc.
- Movetis NV
- New Pervasis Therapeutics, Inc.
- NPS Pharmaceuticals, Inc.
- Premacure AB
- Prism Pharmaceuticals, Inc.
- River Pharmaceuticals
- Roberts Pharmaceutical Corporation
- SARcode Corporation
- SuppreMol GmbH
- Synovis Life Technologies, Inc.
- Transkaryotic Therapies, Inc.
- ViroPharma Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice